Management of oral and gastrointestinal mucosal injury: ESMO Clinical Practice Guidelines for diagnosis, treatment, and follow-up

Annals of Oncology

Volumn 26, Issue , 2015, Pages v139-v151

  Peterson, D E ^a   Boers Doets, C B ^b   Bensadoun, R J ^c   Herrstedt, J ^d  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c Centre Haute Energie   (France)

^d ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

AMLEXANOX; BEVACIZUMAB; BICARBONATE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ERLOTINIB; ETOPOSIDE; EVEROLIMUS; FLUOROURACIL; FOLINIC ACID; GEFITINIB; IFOSFAMIDE; IRINOTECAN; LAPATINIB; METHOTREXATE; MOUTHWASH; NAVELBINE; NONSTEROID ANTIINFLAMMATORY AGENT; OXALIPLATIN; PACLITAXEL; PARACETAMOL; RAPAMYCIN; SORAFENIB; SUNITINIB; TEGAFUR; UNINDEXED DRUG; VINCRISTINE;

ARTICLE; CANCER RADIOTHERAPY; DIARRHEA; ESOPHAGITIS; FOLLOW UP; GASTROINTESTINAL MUCOSA; GASTROINTESTINAL MUCOSA INJURY; GRAFT VERSUS HOST REACTION; HEAD AND NECK CANCER; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MOUTH HYGIENE; MUCOSA INFLAMMATION; ORAL MUCOSITIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK ASSESSMENT; STOMATITIS; SYSTEMATIC REVIEW; XEROSTOMIA; DISEASE MANAGEMENT; GASTROINTESTINAL TRACT; INJURIES; MOUTH MUCOSA; MUCOSITIS; PATHOLOGY;

DISEASE MANAGEMENT; GASTROINTESTINAL TRACT; HUMANS; MOUTH MUCOSA; MUCOSITIS;

EID: 84941645551     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdv202     Document Type: Article

References (46)

1. Peterson DE, Bensadoun RJ, Roila F. Management of oral and gastrointestinal mucositis: ESMO Clinical Practice Guidelines. Ann Oncol 2011; 22(Suppl 6): vi78-vi84.
2. Keefe DM, Schubert MM, Elting LS et al. Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer 2007; 109: 820-831.
3. Lalla RV, Bowen J, Barasch A et al. MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer 2014; 120: 1453-1461.
4. Boers-Doets CB, Raber-Durlacher JE, Treister NS et al. Mammalian target of rapamycin inhibitor-associated stomatitis. Future Oncol 2013; 9: 1883-1892.
5. Nugent B, Lewis S, O'Sullivan JM. Enteral feeding methods for nutritional management in patients with head and neck cancers being treated with radiotherapy and/or chemotherapy. Cochrane Database Syst Rev 2013; 1: CD007904.
6. Koyfman SA, Adelstein DJ. Enteral feeding tubes in patients undergoing definitive chemoradiation therapy for head-and-neck cancer: a critical review. Intl J Radiat Oncol Biol Phys 2012; 84: 581-589.
7. Williams GF, Teo MT, Sen M et al. Enteral feeding outcomes after chemoradiotherapy for oropharynx cancer: a role for a prophylactic gastrostomy? Oral Oncol 2012; 48: 434-440.
8. Rutter CE, Yovino S, Taylor R et al. Impact of early percutaneous endoscopic gastrostomy tube placement on nutritional status and hospitalization in patients with head and neck cancer receiving definitive chemoradiation therapy. Head Neck 2011; 33: 1441-1447.
9. Silander E, Nyman J, Bove M et al. Impact of prophylactic percutaneous endoscopic gastrostomy on malnutrition and quality of life in patients with head and neck cancer: a randomized study. Head Neck 2012; 34: 1-9.
10. SFNEP (Societe Francophone de Nutrition Enterale et Parenterale) SFNEP Oncology Nutrition Guidelines. In: Nutrition Clinique et Métabolisme, Vol. 26 (4), 2012; http://www.em-consulte.com/revue/NUTCLI/26/4/table-des-matieres/: (20 April 2015, date last accessed).
11. Bachmann P, Romero G, Deneuve S et al. Référentiel de pratiques professionnelles: prise en charge nutritionnelle des cancers des voies aérodigestives supérieures. Nutr Clin Métab 2014; 28: 207-215.
12. French Speaking Society of Clinical Nutrition and Metabolism. Clinical nutrition guidelines of the French Speaking Society of Clinical Nutrition and Metabolism (SFNEP): summary of recommendations for adults undergoing non-surgical anticancer treatment. Dig Liver Dis 2014; 46: 667-674.
13. National Cancer Institute PDQ®. Oral mucositis. In Oral Complications of Chemotherapy/Head & Neck Radiation; http://www.cancer.gov/cancertopics/pdq/supportivecare/oralcomplications/HealthProfessional/page5 (9 April 2015, date last accessed).
14. Sonis S, Treister N, Chawla S et al. Preliminary characterization of oral lesions associated with inhibitors of mammalian target of rapamycin in cancer patients. Cancer 2010; 116: 210-215.
15. Watters AL, Epstein JB, Agulnik M. Oral complications of targeted cancer therapies: a narrative literature review. Oral Oncol 2011; 47: 441-448.
16. Li E, Trovato JA. New developments in management of oral mucositis in patients with head and neck cancer or receiving targeted anticancer therapies. Am J Health Syst Pharm 2012; 69: 1031-1037.
17. Pilotte AP, Hohos MB, Polson KM et al. Managing stomatitis in patients treated with mammalian target of rapamycin inhibitors. Clin J Oncol Nurs 2011; 15: E83-E89.
18. de Oliveira MA, Martins E Martins F, Wang Q et al. Clinical presentation and management of mTOR inhibitor-associated stomatitis. Oral Oncol 2011; 47: 998-1003.
19. Elting LS, Chang YC, Parelkar P et al. Risk of oral and gastrointestinal mucosal injury among patients receiving selected targeted agents: a meta-analysis. Support Care Cancer 2013; 21: 3243-3254.
20. Kwitkowski VE, Prowell TM, Ibrahim A et al. FDA approval summary: temsirolimus as treatment for advanced renal cell carcinoma. Oncologist 2010; 15: 428-435.
21. Rugo HS, Pritchard KI, Gnant M et al. Incidence and time course of everolimusrelated adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2. Ann Oncol 2014; 25: 808-815.
22. Keefe D, Stringer A. The potential successes and challenges of targeted anticancer therapies. Curr Opin Support Palliat Care 2010; 4: 16-18.
23. Harandi A, Zaidi AS, Stocker AM, Laber DA. Clinical efficacy and toxicity of anti-EGFR therapy in common cancers. J Oncol 2009; 2009: 567486 (9 April 2015, date last accessed).
24. Elez E, Macarulla T, Tabernero J. Handling side-effects of targeted therapies: safety of targeted therapies in solid tumours. Ann Oncol 2008; 19(Suppl 7): vii146-vii152.
25. Pessi MA, Zilembo N, Haspinger ER et al. Targeted therapy-induced diarrhea: a review of the literature. Crit Rev Oncol Hematol 2014; 90: 165-179.
26. National Cancer Institute CTCAE; http://evs.nci.nih.gov/ftp1/CTCAE/About.html (9 April 2015, date last accessed).
27. Cooperstein E, Gilbert J, Epstein JB et al. Vanderbilt Head and Neck Symptom Survey version 2.0: report of the development and initial testing of a subscale for assessment of oral health. Head Neck 2012; 34: 797-804.
28. Boers-Doets CB, Lalla RV. The mIAS scale: a scale to measure mTOR inhibitorassociated stomatitis. Support Care Cancer 2013; 21: S140.
29. Lewis SJ, Heaton KW. Stool form scale as a useful guide to intestinal transit time. Scand J Gastroenterol 1997; 32: 920-924.
30. Nutting CM, Morden JP, Harrington KJ et al. Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial. Lancet Oncol 2011; 12: 127-136.
31. McGuire DB, Fulton JS, Park J et al. Systematic review of basic oral care for the management of oral mucositis in cancer patients. Support Care Cancer 2013; 21: 3165-3177.
32. Eilers RE, Jr, Gandhi M, Patel JD et al. Dermatologic infections in cancer patients treated with epidermal growth factor receptor inhibitor therapy. J Natl Cancer Inst 2010; 102: 47-53.
33. Duvic M. EGFR inhibitor-associated acneiform folliculitis: assessment and management. Am J Clin Dermatol 2008; 9: 285-294.
34. Amitay-Laish I, David M, Stemmer SM. Staphylococcus coagulase-positive skin inflammation associated with epidermal growth factor receptor-targeted therapy: an early and a late phase of papulopustular eruptions. Oncologist 2010; 15: 1002-1008.
35. Kajiya K, Sawane M, Huggenberger R, Detmar M. Activation of the VEGFR-3 pathway by VEGF-C attenuates UVB-induced edema formation and skin inflammation by promoting lymphangiogenesis. J Invest Dermatol 2009; 129: 1292-1298.
36. Roigas J. Clinical management of patients receiving tyrosine kinase inhibitors for advanced renal cell carcinoma. Europ Urol Suppl 2008; 7: 593-600.
37. Novartis Pharmaceutical Corp. Highlights of prescribing information; http://www.pharma.us.novartis.com/product/pi/pdf/afinitor.pdf (9 April 2015, date last accessed).
38. Malizzia LJ, Hsu A. Temsirolimus, an mTOR inhibitor for treatment of patients with advanced renal cell carcinoma. Clin J Oncol Nurs 2008; 12: 639-646.
39. Boers-Doets CB, Epstein JB, Raber-Durlacher JE et al. Oral adverse events associated with tyrosine kinase and mammalian target of rapamycin inhibitors in renal cell carcinoma: a structured literature review. Oncologist 2012; 17: 135-144.
40. Scully C. Clinical practice. Aphthous ulceration. N Engl J Med 2006; 355: 165-172.
41. National Cancer Institute. FDA approval for palifermin; http://www.cancer.gov/cancertopics/druginfo/fda-palifermin (9 April 2015, date last accessed).
42. Venkatesh GH, Manjunath VB, Mumbrekar KD et al. Polymorphisms in radioresponsive genes and its association with acute toxicity among head and neck cancer patients. PLoS One 2014; 9: e89079.
43. Sonis S, Antin J, Tedaldi M, Alterovitz G. SNP-based Bayesian networks can predict oral mucositis risk in autologous stem cell transplant recipients. Oral Dis 2013; 19: 721-727.
44. Peterson DE, Keefe DM, Sonis ST. New frontiers in mucositis. In Govindan R (ed.) Am Soc Clin Oncol Educ Book 2012; 545-551.
45. Jensen SB, Peterson DE. Oral mucosal injury caused by cancer therapies: current management and new frontiers in research. J Oral Pathol Med 2014; 43: 81-90.
46. Somerfield MR, Padberg JR, Pfister DG, et al. ASCO clinical practice guidelines: process, progress, pitfalls, and prospects. Class Pap Curr Comments 2000; 4: 881-886.